Pregnancy-Induced Rise in Serum C-Peptide Concentrations in Women With Type 1 Diabetes by Nielsen, Lene Ringholm et al.
Pregnancy-Induced Rise in Serum
C-Peptide Concentrations in Women With
Type 1 Diabetes
LENE RINGHOLM NIELSEN, MD, PHD
1,2




PETER DAMM, MD, DMSC
1,5
ELISABETH R. MATHIESEN, MD, DMSC
1,2
OBJECTIVE — The purpose of this study was to investigate whether pregnancy induces
increased insulin production as a marker of improved -cell function in women with long-term
type 1 diabetes.
RESEARCH DESIGN AND METHODS — This was a prospective study of 90 consec-
utive pregnant women with type 1 diabetes. At 8, 14, 21, 27, and 33 weeks blood samples were
drawn for measurements of A1C, C-peptide, and serum glucose. C-peptide (detection limit: 6
pmol/l) was considered stimulated at a corresponding serum glucose concentration 5.0
mmol/l. GAD antibody concentration was determined at 8 and 33 weeks in 35 women.
RESULTS — C-peptide concentrations gradually increased throughout pregnancy regardless
ofserumglucoseconcentrationsinthe90womenwithamediandurationofdiabetesof17years
(range 1–36 years). Among 35 women with paired recordings of stimulated C-peptide, C-
peptide production was detectable in 15 (43%) at 8 weeks and in 34 (97%) at 33 weeks (P 
0.0001), and median C-peptide gradually increased from 6 to 11 pmol/l (P  0.0004) with a
median change of 50% (range 50 to 3,271%) during pregnancy. GAD antibodies were present
in 77% with no change from 8 to 33 weeks (P  0.85). Multivariate regression analysis revealed
a positive association between the absolute increase in C-peptide concentrations during preg-
nancy and decreased A1C from 8 to 33 weeks (P  0.003).
CONCLUSIONS — A pregnancy-induced increase in C-peptide concentrations in women
with long-term type 1 diabetes was demonstrated, even in women with undetectable C-peptide
concentrations in early pregnancy. This increase is suggestive of improved -cell function and
was associated with improvement in glycemic control during pregnancy.
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P
reviously it has been shown that in-
dividuals with long-term type 1 di-
abetes have scattered -cells in the
pancreas (1) that retain the ability to de-
velop new -cells, probably by neogene-
sis from exocrine duct cells (2,3).
Pregnancy is a unique event in which
the fetus usually survives to full term
without rejection by the maternal im-
mune system, which apparently accepts
theforeignfetus(4).Duringnormalpreg-
nancy, mild suppression of the maternal
immune system occurs to tolerate the al-
logenicfetus(5).Thisrequiressubstantial
changes in the maternal immune system
over a programmed period. Pregnancy is
associated with partial suppression of the
immune inﬂammatory system so that au-
toimmune diseases often go into remis-
sion during pregnancy (5).
During normal pregnancy, growth-
promoting factors are expressed in in-
creased amounts, and the pancreas
responds to the additional demand for
insulin by an enlargement of existing is-
lets of Langerhans and hyperplasia of
the insulin-producing -cells (6,7), up-
regulation of insulin synthesis and secre-
tion (6), and increased sensitivity of
-cells to glucose stimulation (6). In-
creased mitotic activity has been seen
both in vivo and in vitro in islets exposed
togrowthhormone.Receptorsforgrowth
hormone are expressed in islet cells and
are upregulated during pregnancy (8).
In small series of women with long-
term type 1 diabetes, even with previ-
ously undetectable C-peptide secretion,
occurrence of maternal insulin produc-
tion in pregnancy has been observed (9–
11). This phenomenon may be a
consequence of rejuvenated -cell func-
tion due to pregnancy-induced growth-
promoting factors and suppression of the
immune system (9), but improved meta-
boliccontrolmayalsoplayaroleinnewly
diagnosed type 1 diabetes (12) as well as
in type 1 diabetes beyond the initial re-
mission phase (10,13).
The aim of this study was to investi-
gate whether pregnancy induces in-
creased C-peptide concentration as a
markerofpossible-cellregenerationina
large unselected cohort of women with
long-term type 1 diabetes. In addition,
possible factors related to increased C-
peptide concentration were investigated.
RESEARCH DESIGN AND
METHODS— As a part of another
study, a total of 108 consecutive Danish-
speaking Caucasian women with clinical
type1diabetesfor1yearandwithnon-
fasting C-peptide concentrations 600
pmol/l were investigated prospectively
during pregnancy. Details on the materi-
alsandmethodshavebeenpublishedpre-
viously (14). A total of 90 women with





23), 27 (25–29), and 33 (31–35) weeks,
and once within 5 days postpartum,
blood samples were drawn from an ante-
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between breakfast and lunch and centri-
fuged at 3,000g. Serum for C-peptide,
placental growth hormone, and IGF-I
measurements obtained during preg-
nancy was stored at 80°C for later
analysis within one run of an assay. Post-
partum blood samples for C-peptide and
serum glucose were analyzed separately 6
months later. The differences in C-
peptide concentrations and serum glu-
coselevelsbetweenthetworunsofassays
were 0% for C-peptide and 2% for serum
glucose, respectively, tested in 20 repre-
sentative samples.
Serum glucose concentrations were
measured by the glucose-hexokinase
method (Roche Diagnostics, Mannheim,
Germany) with an intra-assay coefﬁcient
of variation (CV) of 1.0% and an interas-
say CV of 1.7%. In 67% of the samples
obtained during pregnancy, glucose con-
centrations were measured immediately;
intheremainingsamplesmeasurementof
serum glucose concentrations was ob-
tained from thawed serum samples.
C-peptide was measured by the elec-
trochemiluminescence immunoassay
ECLIA (Modular 170, Roche Diagnos-
tics). The concentrations in healthy fast-
ing subjects were 180 pmol/l with an
intra-assay CV of 1.9% and an interassay
CV of 2.3%. C-peptide production was
deﬁned as concentrations above the de-
tection limit of 6 pmol/l, whereas C-
peptide concentrations 6 pmol/l were
set to 6 pmol/l.
TosecuremeasurementsofC-peptide
at serum glucose concentrations known
tostimulateC-peptideproduction,theC-
peptide data were post hoc divided into
two groups, i.e., with corresponding
plasma glucose concentrations greater
than or less than 5.0 mmol/l (15). C-
peptide concentrations with correspond-
ing serum glucose concentrations 5.0
mmol/l are arbitrarily stated as “stimu-
lated C-peptide” in the following. Thirty-
ﬁve women had paired stimulated
C-peptide concentrations at 8 and 33
weeks.
GAD antibody concentrations were
determined in early and late pregnancy in
the 35 women with paired stimulated C-
peptide concentrations using a quantita-
tive radioligand assay as described
previously (16). The upper detection
limit was 250 units/ml.
Placental growth hormone and IGF-I
were analyzed as described previously
(17). Serum creatinine was assayed on a
routine basis, and the upper normal limit
was 88 mol/l (18).
Allwomenvisitedourand/ortheirlo-
cal diabetes clinic at 1- or 2-week inter-
valsthroughoutpregnancywhereweight,
A1C, insulin dose, and blood pressure
were recorded. The majority of women
were treated with a basal bolus insulin
regimen. All women registered their self-
monitored plasma glucose (SMPG) read-
ings in diabetes diaries, which were
evaluated at each clinic visit. Routine self-
monitoring was recommended at least
seven times daily to obtain preprandial
SMPG of 4.0–6.0 mmol/l, 90 min post-
prandial SMPG of 4.0–8.0 mmol/l, and
pre-bedtime SMPG of 6.0–8.0 mmol/l
(14).
A1C was measured by a latex immu-
noagglutination inhibition method with
the same analyzer (DCA 2000, Bayer, En-
gland). Normal A1C range outside preg-
nancy was 4.7–6.3%, in early pregnancy
was 4.5–5.7%, and in late pregnancy was
4.4–5.6% (19).
Selective serotonin reuptake inhibitors
weregivenin3womenandantihyperten-
sive therapy, mainly with methyldopa,
was given in 22 women during preg-
nancy. Thyroid dysfunction was treated
withlevothyroxinein15womenandwith
thiamazole in 2 women, resulting in nor-
mal thyroid function in all 17 women
during pregnancy.
All participants gave written in-
formed consent. The research protocol
was approved by the regional committees
for ethics and science and by the Danish
Data Protection Agency.
Statistics
Descriptive statistics are given as median
(range) or number (percent). Categorical
variables were compared by a 
2 test or
Fisher’s exact test as appropriate. Contin-
uous variables were analyzed by Kruskal-
Wallis or Mann-Whitney tests when
appropriate.
Changes during pregnancy were
tested by assessing the within-subject dif-
ferences between continuous values at
week 33 and week 8 using the Kruskal-
Wallis test. McNemar’s test was used for
within-subject differences between
frequencies.
After logarithmic transformation to
improve approximation of the normal
distribution, correlation analyses were
performedusingPearson’scoefﬁcient,de-
noted r. To determine factors associated
with absolute change (after logarithmic
transformation) in C-peptide concentra-
tionsfrom8to33weeks,univariatelinear
regression analyses were conducted with
the following explanatory variables: ma-
ternal age, duration of diabetes, prepreg-
nancyBMI,weightgainduringpregnancy
and decrease in A1C from 8 to 33 weeks,
aswellasinsulindose(internationalunits
per kilogram), A1C (percentage), placen-
tal growth hormone, IGF-I, and GAD an-
tibody concentrations at 8 and 33 weeks.
Signiﬁcantvariableswerefurthertestedin
backward stepwise multivariate linear re-
gression analysis. A variable remaining
signiﬁcantly associated with change in C-
peptide concentration during pregnancy
in this analysis was regarded as an inde-
pendent factor.
Differenceswereconsideredtobesta-
tistically signiﬁcant at two-sided P 
0.05. All statistical analyses were per-
formed using SAS (version 9.1, SAS Insti-
tute, Cary, NC).
RESULTS— The 90 women were me-
dian 31 (range 21–42) years old with a
duration of diabetes of 17 (1–36) years
and a prepregnancy BMI of 24.3 (18.4–
34.4) kg/m
2. At inclusion, A1C was 6.6
(4.9–8.8)%, and insulin dose was 0.75
(0.33–1.17) IU/kg. At each blood sam-
pling time, concentrations of both C-
peptide and corresponding serum
glucose were measured in 87–100% of
women (Table 1).
At 8 weeks, the C-peptide concentra-
tion was detectable in serum in 44% of
women with a corresponding serum glu-
cose concentration 5.0 mmol/l and in
41%ofwomenwithstimulatedC-peptide
(correspondingserumglucoseconcentra-
tion 5.0 mmol/l). Throughout preg-
nancy, these proportions gradually
increased (Table 1), and at 33 weeks, the
C-peptide production was detectable in
97% of women with a corresponding se-
rum glucose concentration 5.0 mmol/l
and in 98% of women with stimulated
C-peptide. Median serum glucose con-
centrations in the groups with concentra-
tions less than and greater than 5.0
mmol/l, respectively, were comparable
throughout pregnancy (Table 1), but the
individual women’s glucose concentra-
tions varied at greater than and less than
5.0 mmol/l at the different sampling
times. C-peptide and serum glucose con-
centrations did not correlate signiﬁcantly
at any sampling time.
Serum creatinine concentrations
were within normal range in all but two
women with concentrations of 89 and 95
mol/latinclusion,increasingto101and
Ringholm Nielsen and Associates
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creasedfromundetectableconcentrations
at inclusion to 10 pmol/l at 33 weeks in
both women.
Table 2 shows data for 35 women
with paired recordings of stimulated C-
peptideconcentrationsat8and33weeks.
The number of women with detectable
C-peptide concentrations increased from
15 (43%) at 8 weeks to 34 (97%) at 33
weeks (P  0.0001) at comparable serum
glucose concentrations. From 8 to 33
Table1—C-peptideconcentrationsduringpregnancyin90womenwithtype1diabetesdividedaccordingtoserumglucosevalues>5.0mmol/l
or <5.0 mmol/l at the time of sampling
8 weeks 14 weeks 21 weeks 27 weeks 33 weeks Postpartum
Women with blood sampling 90 (100) 85 (94) 87 (97) 85 (94) 90 (100) 78 (87)
Number of samples 5.0 mmol/l 32 43 39 28 31 13
Number of samples 5.0 mmol/l 58 42 48 57 59 65
C-peptide concentration (pmol/l) 6 (6–325) 7 (6–598) 7 (6–434) 9 (6–527) 11 (6–472) 6 (6–1,250)
C-peptide concentration (pmol/l) at
serum glucose 5.0 mmol/l 6 (6–194) 7 (6–248) 7 (6–120) 8 (6–308) 9 (6–164) 6 (6–350)
C-peptide concentration (pmol/l) at
serum glucose 5.0 mmol/l 6 (6–325) 7 (6–598) 7 (6–434) 9 (6–527) 13 (6–472) 6 (6–1,250)
Women with C-peptide production 38 (42) 47 (49) 54 (62) 79 (93) 88 (98) 28 (36)
Women with C-peptide production at
serum glucose 5.0 mmol/l 14 (44) 25 (58) 22 (56) 23 (82) 30 (97) 4 (31)
Women with C-peptide production at
serum glucose 5.0 mmol/l 24 (41) 22 (52) 32 (67) 56 (98) 58 (98) 24 (37)
Nonfasting serum glucose concentration
5.0 mmol/l 3.7 (0.8–4.9) 3.6 (1.8–4.9) 3.4 (1.4–4.9) 3.7 (1.8–4.9) 3.5 (2.1–4.9) 4.1 (2.0–4.8)
Nonfasting serum glucose concentration
5.0 mmol/l 7.2 (5.0–14.5) 8.1 (5.1–15.5) 7.0 (5.1–15.5) 6.6 (5.0–14.4) 6.9 (5.0–18.3) 8.4 (5.0–20.9)
Data are given as n (%) or median (range). C-peptide production was deﬁned as concentrations above the detection limit of 6 pmol/l. Concentrations at or below 6
were set to 6 pmol/l.








n (%) 20 (57) 15 (43)
Age (years) 32 (27–40)* 30 (26–34)
Duration of diabetes (years) 20 (6–28) 16 (2–31)
Last A1C before pregnancy (%) 7.5 (6.1–10.0) 7.6 (6.0–9.3)
A1C at 8 weeks (%) 7.1 (5.9–8.7) 6.8 (5.6–8.8)
A1C at 33 weeks (%) 6.0 (5.4–7.2) 6.0 (5.5–7.1)
Median change in A1C from 8 to 33 weeks (%) 0.8 (0.2 to 2.1) 0.6 (0.5 to 2.9)
Insulin dose before pregnancy (IU/kg) 0.75 (0.49–1.05) 0.56 (0.32–1.17)
Insulin dose at 8 weeks (IU/kg) 0.74 (0.45–1.04) 0.77 (0.33–1.14)
Insulin dose at 33 weeks (IU/kg) 1.04 (0.72–1.60) 1.05 (0.52–1.46)
BMI before pregnancy (kg/m
2) 24.2 (18.4–34.4) 23.5 (19.7–33.7)
Weight gain during pregnancy (kg) 14.3 (5.6–26.8) 15.0 (8.0–26.0)
C-peptide concentrations at 8 weeks (pmol/l) 6 22 (7–325)
C-peptide concentrations at 33 weeks (pmol/l) 10 (6–16) 38 (8–472)
Median change in C-peptide concentrations from 8 to 33 weeks (%) 67 (0–167)* 30 (50 to 3,271)
Serum glucose concentrations at 8 weeks (mmol/l) 6.8 (5.5–13.3) 7.7 (5.1–14.5)
Serum glucose concentrations at 33 weeks (mmol/l) 6.7 (5.4–18.3) 7.6 (5.1–12.8)
Placental growth hormone concentrations at 8 weeks (ng/ml) 1.0 (0.1–6.9) 1.3 (0.2–5.2)
Placental growth hormone concentrations at 33 weeks (ng/ml) 36.6 (3.5–157) 41 (8.2–87)
IGF-I concentrations at 8 weeks (ng/ml) 158 (26–234) 169 (100 to 268)
IGF-I concentrations at 33 weeks (ng/ml) 235 (115–483) 280 (144–331)
GAD antibody concentrations at 8 weeks (units/ml) 20.5 (0–250) 7 (0–250)
GAD antibody concentrations at 33 weeks (units/ml) 15 (0–250) 6 (0–129)
Data are median (range) unless indicated otherwise. * P  0.05.
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tion increased from 6 to 11 pmol/l (P 
0.0004)withamedianabsolutechangein
C-peptide concentrations of 50% (range
50 to 3,271%).
Twenty women had undetectable C-
peptide concentrations in early preg-
nancy and were older (P  0.04) with a
tendencytowardlongerdiabetesduration
(P  0.06) compared with 15 women
with detectable C-peptide concentrations
in early pregnancy (Table 2). The C-
peptide concentrations in these women
measured in late pregnancy did not reach
the values of women with detectable val-
ues at inclusion (Fig. 1), but the percent-
age of absolute change in C-peptide
concentrations was highest in the women
with undetectable concentrations at in-
clusion. No differences were detected in
the prevalence of diabetic retinopathy,
hypoglycemia awareness, or severe hypo-
glycemia (requiring assistance from an-
other individual) during pregnancy (data
not shown).
GAD antibodies were present in 27
(77%) of the 35 women. There was a ten-
dency toward higher concentrations
among women with undetectable C-
peptide concentrations at baseline (Table
2), but this did not reach statistical signif-
icance (P  0.14). A decrease in GAD an-
tibody concentrations during pregnancy
could not be detected (P  0.85).
In univariate linear regression analy-
ses,theabsolutechangeinC-peptidecon-
centrations from 8 to 33 weeks was
positively associated with A1C at inclu-
sion (r  0.34; P  0.047) and with a
decrease in A1C from 8 to 33 weeks (r 
0.49; P  0.003). No other signiﬁcant as-
sociationswerefound.Inmultivariatelin-
ear regression analysis, a decrease in A1C
from 8 to 33 weeks was the only variable
associated with an absolute change in C-
peptide concentrations (parameter esti-
mate: 50 [95% CI 20–80], P 
0.003). This means that C-peptide con-
centration increases 50 pmol/l per per-
cent decrease in A1C.
CONCLUSIONS— In this prospec-
tive study of 90 pregnant women with
long-term type 1 diabetes, we demon-
strated gradually increasing C-peptide
concentrations in serum throughout
pregnancy. Even in women with unde-
tectable stimulated C-peptide concentra-
tions in early pregnancy, a signiﬁcant
increase in stimulated C-peptide concen-
trations was obtained in late pregnancy.
This increase was associated with an im-
provement in glycemic control during
pregnancy.
These ﬁndings are in extension of
preliminary observations of rejuvenation
of-cellfunctioninearlypregnancyin10
womenwithlong-termtype1diabetes(9)
and in 23 type 1 diabetic women during
the entire pregnancy (11). In the current
study, detectable C-peptide production
was present in 42% of women in early
pregnancy, which is comparable with re-
cent ﬁndings in nonpregnant type 1 dia-
betic subjects with comparable duration
of diabetes and good metabolic control
(20).
C-peptide does not cross the placenta
in either direction and, consequently, the
C-peptide concentrations detected in the
current study originate from the mother
and not from the developing fetus. Like-
wise it is not likely that the increase seen
in C-peptide concentrations is due to
cross-reactivity with other pregnancy-
related hormones (9). To avoid overesti-
mation of the increase in C-peptide
concentrations in the subset of women
with C-peptide concentrations below the
detection limit in early pregnancy, these
concentrations were all set to 6 pmol/l
(detection limit).
Serum glucose concentrations were
measured immediately in the majority of
samples. However, for practical reasons,
in a minority of samples, serum glucose
concentrations were assayed on stored
samples, which might reveal slightly
lower concentrations due to intermediate
glucose metabolism.
For practical reasons standardized
samplingeitherinthefastingstateorafter
a standardized meal was not performed.
To compensate for this weakness of the
study, a post hoc analysis of women with
paired C-peptide measurements at serum
glucose concentrations known to stimu-
late C-peptide production (15) was per-
formed, and a signiﬁcant increase in
C-peptide concentration during preg-
nancy was demonstrated in this sub-
group. Surprisingly, the C-peptide
concentrations measured at serum glu-
cose concentrations 5 mmol/l were
comparable with the concentrations mea-
sured at stimulated serum glucose con-
centrations. The explanation for this
ﬁndingremainsspeculative.Theduration
of the low serum glucose concentrations
is unknown, and it is not known whether
the relatively immature and stressed
-cells of these pregnant women are able
to produce signiﬁcant differences in C-
peptide concentrations with the relatively
smalldifferenceinserumglucoseconcen-
trations detected in this study.
In normal rodents, the number of in-
sulin-producing -cells increases during
pregnancy, and the sensitivity to secreta-
gogues is increased in the islet -cells (7).
Another recent study of pregnant, nondi-
abetic mice showed a 2-fold increase in
-cellmassduringpregnancy(21).Inhu-
man studies, the area of the pancreatic
endocrine tissue doubles during normal
pregnancy, and hyperplasia of the -cells
is demonstrated (7). The demonstrated
Figure 1—A: Paired recordings of stimulated C-peptide concentration in 15 pregnant women
with type 1 diabetes and C-peptide production in early pregnancy. B: Paired recordings of stim-
ulated C-peptide concentration in 20 pregnant women with type 1 diabetes without C-peptide
production in early pregnancy. Detection limit was 6 pmol/l. C-peptide concentration is indicated
on a logarithmic scale.
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currentstudymaythusreﬂectpregnancy-
induced hyperplasia of the existing
-cells. Such a mechanism is supported
by the rapid decline in the circulating C-
peptide concentration postpartum. How-
ever,-cellneoplasiamayalsobepresent,
whichissupportedbytheautopsyﬁnding
of insulin-positive -cells in 88% of pa-
tients with long-standing type 1 diabetes
(2). In that study, the histological investi-
gations suggested that new -cells are
formedthroughdifferentiationofprogen-
itor cells as duct cells or putative stem
cells (2). In healthy pregnant women a
similar increase in C-peptide concentra-
tion during pregnancy has been reported
(7,10,11).
The mechanisms underlying the in-
creased C-peptide production demon-
strated in the present study remain
unknown. Menin, a protein previously
characterized as an endocrine tumor sup-
pressor and transcriptional regulator,
controls islet growth in pregnant, nondi-
abetic mice (21). Further studies of pos-
sible growth promoters during human
pregnancy are warranted.
In the current study, the increased C-
peptide concentrations were associated
with improved metabolic control during
pregnancy. This ﬁnding is in accordance
with previous ﬁndings of an association
between better metabolic control and the
presence of C-peptide production in
pregnant (11) and nonpregnant patients
with type 1 diabetes (10,12,13,22). It is
not known whether improved metabolic
control results in C-peptide production
or, vice versa, whether the increased C-
peptide production results in improved
metabolic control. However, a prospec-
tive randomized trial demonstrated that
improved metabolic control leads to in-
creased C-peptide concentrations in pa-
tients with short-term type 1 diabetes
(13), and in the current study the in-
creased C-peptide concentrations were
notassociatedwithareducedinsulindose
in late pregnancy, leading us to suggest
thattheimprovedmetaboliccontrolfacil-
itated C-peptide production. In postmor-
tum analysis of pancreatic tissue from
patients with type 1 diabetes, the number
of -cells was independent of duration of
diabetes but was higher in patients with
lower blood glucose concentrations (2).
This ﬁnding may indicate that obtaining
and maintaining good metabolic control
in pregnancy plays a pivotal role in the
regeneration of insulin-producing -cells
during pregnancy.
C-peptide concentrations may be ele-
vated in renal disease (23). It is unlikely
that this confounds the present results as
the renal clearance is generally increased
during pregnancy (24), which may in-
deed underestimate the C-peptide con-
centrations. Notably, serum creatinine
remained within the normal range
throughout pregnancy in the vast major-
ity of our patients (18).
During normal pregnancy mild ma-
ternal immunosuppression occurs to tol-
erate the allogenic fetus (5). This may
resultinmetabolicallyimportantregener-
ation of -cell function. We could not
demonstrate a relation between changes
in GAD antibody concentration and re-
generationof-cellfunctionduringpreg-
nancy, in agreement with Novak et al.
(10), who did not detect any association
between C-peptide positivity during
pregnancy and the presence of antibodies
against GAD, insulinoma antigen 2, or in-
sulin (10). A possible role of pregnancy-
induced changes in other aspects of the
immune system cannot be ruled out.
Increased mitotic activity has been
seen both in vivo and in vitro in islets
exposed to growth hormone (8), suggest-
ing that this hormone may have played a
role in the increasing C-peptide concen-
trations during pregnancy. Combination
therapywithepidermalgrowthfactorand
gastrin induces neogenesis of human islet
-cells from pancreatic duct cells and an
increase in functional -cell mass (3). In
the current study we demonstrated a sig-
niﬁcant increase in placental growth hor-
mone and IGF-I during pregnancy (17),
but associations between these growth
promotors and increased C-peptide pro-
duction during pregnancy could not be
demonstrated. However, because of the
relatively small number of pregnant
women with paired recordings of stimu-
lated C-peptide and the small number of
growth promoters examined, an associa-
tion between pregnancy-related growth
promoters and increased C-peptide pro-
duction could not be excluded.
In the current study, C-peptide con-
centrations decreased rapidly postpar-
tum. This may imply that the increasing
C-peptide concentrations demonstrated
during pregnancy may be generated by
placenta-derived growth promoters or
hormonal factors that are not lasting after
pregnancy. In favor of this hypothesis is
the ﬁnding in mice of a pregnancy-
stimulated proliferation of maternal ro-
dent pancreatic islet -cells with a
promptdeclineintheproliferationwithin
4dayspostpartum(21).Alternatively,the
increasing C-peptide concentrations dur-
ing pregnancy may be ascribed to inter-
ference with other substances. However,
the C-peptide assay used in our study
measures C-peptide accurately and spe-
ciﬁcally (25).
In summary, a pregnancy-induced
increase in C-peptide concentrations in
women with long-term type 1 diabetes
was demonstrated, even in women with
undetectable C-peptide concentrations in
early pregnancy.
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